Successful use of recombinant factor VIIa in a patient with intractable bleeding during extracorporeal membrane oxygenation.
Bleeding is still the most common complication during extracorporeal membrane oxygenation (ECMO) for temporary cardio-circulatory support. We present a case of a young man suffering from intractable hemorrhage during ECMO support, who was pre-treated with glycoprotein IIb/IIIa receptor antagonist Tirofiban due to a suspicion of myocardial ischemia. After failure of conventional hemostatic means, hemostasis was achieved by the donation of recombinant Factor VIIa (rFVIIa). Aspects of bleeding control during extracorporeal circulatory support, the use of Tirofiban and rFVIIa are discussed.
Brose
S
S
Department of Cardiac Surgery, Heart Center Dresden, University of Dresden, Dresden, Germany. s.brose@herzzentrum-dresden.com
Sirbu
H
H
Engel
M
M
Kuhlen
R
R
Autschbach
R
R
D000293:Adolescent; D015199:Extracorporeal Membrane Oxygenation; D015942:Factor VIIa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D015942:Factor VIIa